article thumbnail

FDA generic drug approvals rose in 2023 in bid for improved access

Pharmaceutical Technology

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

article thumbnail

Novartis forecasts improving generic drug business as it weighs unit's future

Bio Pharma Dive

The pharmaceutical company is considering selling or splitting off its struggling Sandoz division and expects to give an update by the end of the year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis begins plans to spin off generic drug business

Bio Pharma Dive

After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

article thumbnail

CpHI Europe: Quality improvements key for the surviving the generic drugs market

Pharmaceutical Technology

Experts discuss the key trends in quality improvements and API reshoring for the generic drugs market at CpHI Europe.

article thumbnail

The Role of Pharmacokinetics in Generic Drugs

Drug Patent Watch

Pharmacokinetics (PK) plays a crucial role in the development and approval of generic drugs. PK studies help ensure that generic drugs are bioequivalent to their brand-name counterparts, meaning they have similar absorption, distribution, metabolism, and excretion (ADME) profiles.

article thumbnail

Patient Centricity in Generic Drug Development: Best Practices

Drug Patent Watch

Patient centricity has become a crucial aspect of the pharmaceutical industry, particularly in the development of generic drugs. Here, we will explore the best practices in patient centricity for generic drug development… Source

article thumbnail

Optimizing Partnerships for Generic Drug Development Success

Drug Patent Watch

The generic drug market has experienced significant growth over the past few decades, driven by the passage of the Hatch-Waxman Act in 1984 and subsequent legislation. Today, the market is more competitive than ever, with generic drugs accounting for over 90% of all prescriptions in the United States.